Christopher D Byrne

81PUBLICATIONS
322CO-AUTHORS
Behavioural epidemiologyMetabolic medicineTe ariā o ngā tauira panoni hauora o te Māori (Māori theory of change models for health)Medical infection agents (incl. prions)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (81)

|Sep 30, 2026
Comparative hepatic effectiveness of empagliflozin vs dapagliflozin among individuals with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease.

|Sep 10, 2026
Heart-liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework.

|Jul 17, 2026
Characteristics and Outcomes of Patients With Imaging-Defined MASLD and Histological Steatosis Grade S0.

|Jun 20, 2026
Burden and Regional Disparities of MASH-Related Liver Cancer in the Asia-Pacific Region From 1990 to 2023.

|May 21, 2026
MASLD prevalence, incidence and global aspects.

|Mar 14, 2026
Hepatocyte SLCO4C1 is a cAMP uptake transporter for inhibiting lipogenesis and a therapeutic target for MASLD.

Xiaojia Huang, Sen Liang, Nan Zhao

Pageof 14

Frequent Collaborators

45 joint publications

Giovanni Targher

24 joint publications

Minghua Zheng

10 joint publications

Herbert Tilg

9 joint publications

Seungho Ryu